Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 130 participants.
Also called NCT06381947
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 130 participants
- Sponsor
- University of Salerno
- Registry
-
NCT06381947
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT06381947. Randomized; no masking; primary purpose prevention. Start 2024-05-01 (anticipated); primary completion 2025-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients
- Acronym
- BESAFE
- Condition
- Dyslipidemias
- Condition
- Statin Adverse Reaction
- Condition
- Cardiovascular Diseases
- Condition
- Lipid Metabolism Disorders
- Intervention (Drug)
- Lipid-lowering therapy combination with PCSK9 inhibitors, bempedoic acid and ezetimibe
- Intervention (Drug)
- Lipid-lowering therapy combination with PCSK9 inhibitors and ezetimibe
- Lead sponsor
- University of Salerno
Record details
- Record id
cardio:ct-nct06381947- Content hash
b29d4c70f0fe636b7020e4136e721f12059e6573f8950cba1383840f3c4eeb02